841 related articles for article (PubMed ID: 20414205)
1. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Weiner LM; Surana R; Wang S
Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205
[TBL] [Abstract][Full Text] [Related]
2. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
3. Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley JL; Dahut WL
Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
[No Abstract] [Full Text] [Related]
4. Cancer immunotherapy--revisited.
Lesterhuis WJ; Haanen JB; Punt CJ
Nat Rev Drug Discov; 2011 Aug; 10(8):591-600. PubMed ID: 21804596
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies for cancer immunotherapy.
Weiner LM; Dhodapkar MV; Ferrone S
Lancet; 2009 Mar; 373(9668):1033-40. PubMed ID: 19304016
[TBL] [Abstract][Full Text] [Related]
6. Cocktails for cancer with a measure of immunotherapy.
Ledford H
Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
[No Abstract] [Full Text] [Related]
7. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.
Melero I; Martinez-Forero I; Dubrot J; Suarez N; Palazón A; Chen L
Clin Cancer Res; 2009 Mar; 15(5):1507-9. PubMed ID: 19240168
[TBL] [Abstract][Full Text] [Related]
8. The role of membrane complement regulatory proteins in cancer immunotherapy.
Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
[TBL] [Abstract][Full Text] [Related]
9. Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N
Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.
Peggs KS; Quezada SA; Allison JP
Clin Exp Immunol; 2009 Jul; 157(1):9-19. PubMed ID: 19659765
[TBL] [Abstract][Full Text] [Related]
11. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
12. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
15. New approaches for cancer immunotherapy.
Karlitepe A; Ozalp O; Avci CB
Tumour Biol; 2015 Jun; 36(6):4075-8. PubMed ID: 25934338
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
Weber JS
Melanoma Res; 2006 Oct; 16(5):379-83. PubMed ID: 17013086
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 blockade: autoimmunity as treatment.
Kapadia D; Fong L
J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
[No Abstract] [Full Text] [Related]
18. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
19. Using antibodies in tumour immunotherapy.
Schultes BC; Nicodemus CF
Expert Opin Biol Ther; 2004 Aug; 4(8):1265-84. PubMed ID: 15268661
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
